Allena Pharmaceuticals, Inc. Book value per Share

Book value per Share of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Book value per Share growth rates and interactive chart. Book value per common share (or, simply book value per share - BVPS) is a method to calculate the per-share value of a company based on common shareholders' equity in the company. Should the company dissolve, the book value per common share indicates the dollar value remaining for common shareholders after all assets are liquidated and all debtors are paid. It is calculated as Total Shareholder's Equity minus Preferred Equity and divided by the number of shares outstanding.


Highlights and Quick Summary

  • Book value per Share for the quarter ending March 31, 2022 was 0.13 (a -53.17% decrease compared to previous quarter)
  • Year-over-year quarterly Book value per Share decreased by -38.59%
  • Annual Book value per Share for 2021 was 0.28 (a -60.02% decrease from previous year)
  • Annual Book value per Share for 2020 was 0.69 (a -10.46% decrease from previous year)
  • Annual Book value per Share for 2019 was 0.78 (a -67.48% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Book value per Share of Allena Pharmaceuticals, Inc.

Most recent Book value per Shareof ALNA including historical data for past 10 years.

Interactive Chart of Book value per Share of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Book value per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 0.13
2021 0.28 0.34 0.21 0.43 0.28
2020 0.69 0.5 0.68 0.43 0.69
2019 0.78 1.07 1.8 1.86 0.78
2018 2.38 2.82 3.25 3.64 2.38
2017 18.33 16.21 0.0 0.0 18.33
2016 0.0 27.22
2015 0.0 48.24

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.